Skip to main content

Table 1 Baseline characteristics of studies reporting on incidence of resistance

From: Systematic review of influenza resistance to the neuraminidase inhibitors

   Study Intervention Patients
Study first author Recruitment
Period
Design* Quality score** Purpose Dose Duration Immunostatus In/ Out Age group
Zanamivir studies
Boivin31 1997-1998 RCT High Treatment 10 mg td 5 days Competent Out Unclear
Hedrick36 1998-1999 RCT High Treatment 10 mg td 5 days Competent Out Children
Ambrozaitis29 1997-2000 RCT High Prophylactic 10 mg td 14 days Competent In Adults
Gravenstein32 1997-2000 RCT High Prophylactic 10 mg td 14 days Competent In Adults
Hayden(1)34 1999-2000 RCT High Prophylactic 10 mg td 10 days Competent Out Adults
Peramivir study
Barosso(a)30 1999-2000 RCT High Treatment 100, 200, or 400 mg qd, or 200 md q12 h 5 days Competent Out Adults
Barosso(b)30 1999-2000 RCT High Treatment 800 mg qd(day1) then400 mg q24 or 400 mg q24 5 days Competent Out Adults
Barosso(c)30 1999-2000 RCT High Treatment 50, 200, or 400 mg qd 5 days Competent Out Adults
Barosso(d)30 1999-2000 RCT High Treatment 200, 400 or 800 mg 5 days Competent Out Adults
Oseltamivir studies
Whitley38 1998-1999 RCT High Treatment 2 mg/kg twice daily (max 100 mg/day) 5 days Competent Out Children
Hayden(2)35 2000-2001 RCT High Prophylactic 75 mg once daily 10 days Competent Out Mix
Hayden(3-a)33 2000 RCT High Treatment 75 mg/150 mg once/twice daily 5 days Competent Out Adult
Hayden (3-b)33 2000 RCT High Treatment 75 mg once daily 5 days Competent Out Adult
Hayden (3-c)33 2000 RCT High Prophylactic 75 mg once daily 7 days Competent Out Adult
Ison37 Before 2009 RCT High Prophylactic 75 mg orally or suspension once daily for age = > 13, weight-based or suspension for age < 13 12 days Compromised In Unclear
Kiso15 2002-2003 OBS 6/6 Treatment 4 mg/kg 2-5 days Competent Mix Children
Kawai42 2003-2004 OBS 6/6 Treatment 75 mg twice daily for adults and children > 35 kg, weight-based twice daily for children < 35 kg 5 days Unclear Out Mix
Hatekayama41 2004-2005 OBS 5/6 Treatment Unclear Unclear Mix Unclear Children
Stephenson43 2005-2007 OBS 6/6 Treatment Twice daily weight-based dosing regimen 5 days Competent Unclear Mix
Cost39 2009 OBS 4/6 Prophylactic Unclear Unclear Compromised In Children
Harvala40 2009 OBS 6/6 Treatment Unclear Unclear Mix Unclear Unclear
Tramontana44 2009 OBS 6/6 Treatment Varied across patients Up to 43 days Compromised In Adults
Wang45 2009 OBS 6/6 Treatment Unclear Unclear Mix In mix
Winzer46 2009 OBS 5/6 Treatment Unclear Unclear Unclear Unclear mix
  1. *Study design is either a randomized clinical trial (RCT) or an observational study (OBS)
  2. **Quality scores for RCTs range from 1 to 4. Study scores for OBSs range from 1 to 6. Low scores indicate low quality, high scores indicate high quality.